Cullinan Q2 FY26 net loss narrows 23.36% to $53.7 million

Reuters2026/08/06 11:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cullinan Therapeutics posted a Q2 net loss of USD 53.7 million, narrowing from USD 70.1 million a year earlier.
R&D expense fell to USD 44.4 million from USD 61 million, while G&A expense dropped to USD 12.8 million from USD 14.8 million.
Cash, cash equivalents, investments, and interest receivable totaled USD 356 million at June 30, 2026; runway expected into 2029.
CLN-049 potentially registrational Phase 2 study in relapsed/refractory AML set to start in Q3 2026, following an End-of-Phase 1 FDA meeting.
Nadim Ahmed said the company expects additional 2026 clinical data readouts for CLN-978 and velinotamig as programs advance toward Phase 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cullinan Q2 FY26 net loss narrows 23.36% to $53.7 million

You may also like

Crypto prices